CURE highlights prostate cancer advancements from Day One of the 2026 ASCO Genitourinary Cancers Symposium.

More than 17,000 individuals with cancer died from their malignancy within a year of their diagnosis during the COVID-19 pandemic than expected based on previous trends.An evaluation of 1-year ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC; Real‑world evidence showed Pluvicto achieved longer PFS when init ...

Incidental detection has increased with ubiquitous CT/MRI, inflating early-stage ‘small renal mass’ diagnoses and complicating interpretation of a ~5% rise in <50-year incidence. Obesity, hypertension ...

In 2026, an estimated 158,850 new cases of colorectal cancer (CRC) will be diagnosed, and 55,230 people will die from the disease in the United States. The Alaska Native population has the highest CRC ...

February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...

Calhoun County’s health profile reflects many of Alabama’s most persistent challenges: shorter life expectancy, widespread chronic disease and uneven access to preventive care. Data from the Centers ...

The line Joe Biden used to put into nearly every big speech — “I’ve never been more optimistic about America’s future” — is a long way from what he says in private now.

In today’s Pharma Pulse, the FDA unveils a Plausible Mechanism framework to fast-track ultra-rare disease therapies, while ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

A new study led by researchers at The University of Texas MD Anderson Cancer Center found that prostate cancer patients with low testosterone levels may have a higher risk of cancer progressing to a ...